Erchen Decoction Ameliorates Lipid Metabolism by the Regulation of the Protein CAV-1 and the Receptors VLDLR, LDLR, ABCA1, and SRB1 in a High-Fat Diet Rat Model
Erchen Decoction Ameliorates Lipid Metabolism by the Regulation of the Protein CAV-1 and the Receptors VLDLR, LDLR, ABCA1, and SRB1 in a High-Fat Diet Rat Model
复制标题
二陈汤通过调节高脂饮食大鼠模型中蛋白质 CAV-1 和受体 VLDLR、LDLR、ABCA1 和 SRB1 改善脂质代谢
DOI：
10.1155/2018/5309490
复制
发表时间：
2018-01-01
影响因子：
--
通讯作者：
Gao, Bizhen
中科院分区：
文献类型：
--
作者：
Ding, Shanshan;Kang, Jie;Gao, Bizhen
脂代谢紊乱是一种常见的以血脂异常为特征的代谢紊乱。二陈汤是治疗痰湿阻络型疾病的传统方剂。据报道，它可以改善脂质代谢紊乱。本研究旨在探讨ECD对高脂饮食（HFD）诱导的大鼠脂代谢紊乱的影响及其机制。将ECD（4.35g/kg/d）和阿托伐他汀（10 mg/kg/d，阳性对照）经口给予HFD喂养的大鼠四周。观察各组动物的摄食量、饮水量、体重、身长、肝脏和内脏脂肪重量、血脂和脂质转运蛋白的含量。实时荧光定量PCR和蛋白质印迹法检测ECD对脂质转运因子mRNA和蛋白质表达水平的影响。本研究表明，ECD能改善高脂饮食大鼠血脂和脂质转运蛋白的紊乱，（0.70±0.08 mmol/L，p<0.01），LDL-C（1.50±0.19 mmol/L，p<0.01），LDL（1.38±0.21 mmol/L，p<0.05），oxLDL（1.77± 0.39ng/mL，p<0.05），而HDL-C（0.87±0.13 mmol/L，p<0.01）、FFA（0.62±0.13 mmol/L，p<0.05）、HDL（38.8±4.0 mg/dL，p<0.05）和CETP（903.6±120.0 ng/mL，p<0.05）上调。而ECD对食物/水/能量摄入量、体重/组织（肝脏和脂肪）重、BMI等指标无明显影响（p>0.05）。同时，ECD逆转了肝脏和内脏脂肪中这些脂质转运因子的异常表达。
Lipid metabolism disorder is a common metabolic disorder characterized by abnormal lipid levels in blood. Erchen decoction (ECD) is a traditional Chinese medicine prescription, which is used for the treatment of diseases caused by retention of phlegm dampness. It has been reported to ameliorate the disorder of lipid metabolism. The aim of the present study was to investigate the effects and underlying mechanisms of ECD in lipid metabolism disorder induced by a high-fat diet (HFD) in rats. ECD (4.35g/kg/d) and atorvastatin (10mg/kg/d, positive control) were orally administered to HFD-fed rats for four weeks. The parameters, food, water consumption, body weight, body length, liver, and visceral fat weight and the content of serum lipids and lipid transporters were assessed. The effects of ECD on the mRNA and protein expression levels of lipid transport factors were measured by real-time PCR and western blotting. The present study demonstrated that ECD improved the disorders of serum lipid and lipid transporters in HFD-fed rats, TG (0.70±0.08 mmol/L, p<0.01), LDL-C (1.50±0.19 mmol/L, p<0.01), LDL (1.38±0.21 mmol/L, p<0.05), and oxLDL (1.77±0.39 ng/mL, p<0.05) were downregulated, while HDL-C (0.87±0.13 mmol/L, p<0.01), FFA (0.62±0.13 mmol/L, p<0.05), HDL (38.8±4.0 mg/dL, p<0.05), and CETP (903.6±120.0 ng/mL, p<0.05) were upregulated. But ECD obviously had no effects on the indices food/water/energy intake, body/tissue (liver and fat) weight, and BMI (p>0.05). Concomitantly, ECD reversed the abnormal expressions of those lipid transport factors in the liver and visceral fat.